Business Context and Reporting Period
This Form 8-K, dated April 6, 2004, discloses a material change in Abbott Laboratories' business segment reporting structure effective January 1, 2004. The reclassification stems from shifts in reporting responsibilities for certain products previously included in U.S. Hospital Products Sales, aligning with the anticipated spin-off of Hospira.
Key Financial Metrics and Segment Reclassifications
The filing provides a detailed reconciliation of 2003 sales figures (in millions) to reflect the new segment structure. Total consolidated sales remain unchanged at $19,681 million for the full year 2003.
| Segment | As Reported FY03 | Reclassification | New Business Segment FY03 |
|---|---|---|---|
| U.S. Pharmaceutical Sales | $5,220 | +$831 | $6,051 |
| U.S. Hospital Products Sales | $3,078 | ($1,040) | $2,038 |
| Ross Products (U.S.) Sales | $2,136 | $0 | $2,136 |
| Worldwide Diagnostic Sales | $3,040 | $0 | $3,040 |
| International Division Sales | $5,685 | $0 | $5,685 |
| Other Sales | $522 | +$209 | $731 |
| Total Sales | $19,681 | $0 | $19,681 |
Material Changes Versus Prior Period
The primary material change is the reclassification of proprietary hospital pharmaceuticals and specific medical devices:
- U.S. Pharmaceutical Sales: Increased by $831 million to include proprietary hospital pharmaceuticals (e.g., Ultane, Zemplar) previously reported under U.S. Hospital Products.
- U.S. Hospital Products Sales: Decreased by $1,040 million. This segment now primarily reflects the domestic core hospital businesses expected to be spun off as Hospira.
- Other Sales: Increased by $209 million to include Abbott Vascular Devices and Spinal Concepts, which were previously part of U.S. Hospital Products Sales.
- International Division: No immediate reporting changes were made to international hospital business prior to the spin-off, though future reporting will separate pharmaceuticals and nutritionals components.
Guidance, Outlook, and Management Commentary
Management indicates that the U.S. Hospital Products segment is expected to be spun off as the major operating component of Hospira. Following the spin-off, Abbott will report the International Division by its pharmaceuticals and nutritionals components. The filing notes that a subsequent 8-K will reflect the final segment reporting structure after the spin-off is completed. The filing does not provide specific forward-looking revenue guidance, profit margins, cash flow projections, or debt levels for the upcoming period.
Investor Verification Checklist
- Verify the exact timing of the Hospira spin-off to understand when the final segment reporting structure will be implemented.
- Confirm the composition of the "Other Sales" segment post-spin-off, specifically regarding the retention of Abbott Vascular Devices and Spinal Concepts.
- Review future filings for the reclassification of international hospital pharmaceuticals into the International Division's pharmaceuticals component.
- Compare the new segment sales figures against historical data to ensure accurate year-over-year growth analysis.